RGT

ARGENTBIO FPO [RGT]
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Healthcare · ASX Small Cap
$0.0550 +10.0%

Updated 29 Jul 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-07-08
Get alerts when RGT triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track RGT — Free

Active Signals

Bullish Signals

  • Stochastic just turned bullish from a low level — early reversal sign
  • Trading above both moving averages — the trend is your friend here
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Beating the Small Ords index — relative strength of 1.57, so it's outpacing the pack
  • Critical cash runway (0.8 quarters)
  • Strong revenue growth (+3905%)
  • Near 52-week low (6% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (2 events)
  • Dilution velocity warning (2 raises recently)
  • CANSLIM S: Tight float (25%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 62% over the past year
  • Revenue growing at +3905% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (65.62%/day)
  • Altman Z-Score distress zone (-1.59 < 1.81, low-confidence approx)
  • Elevated dilution risk (2 recent capital raises)
  • ASX200 bullish (+1.1% 5d)
  • RBA hiking (-3pts)
  • Dilution risk: technical breakout with recent capital raise
  • Calendar: Quarterly 4C in 4d (+5pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (2/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Sentiment trap: strong technicals but weak fundamentals

Recent Catalysts

LOW Quarterly Activities/Appendix 4C Cash Flow Report
NONE Notification of cessation of securities - RGT
NONE s708A(12C)(e) Cleansing Notice
NONE Notification regarding unquoted securities - RGT

Recent ASX Announcements

2026-07-27 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE
2026-07-17 Notification of cessation of securities - RGT
2026-07-14 s708A(12C)(e) Cleansing Notice
2026-07-14 Notification regarding unquoted securities - RGT
2026-07-14 Proposed issue of securities - RGT

Key Metrics

$5.8M
Market Cap
1.3M
Avg Volume
1.0x
Vol Ratio
$0.03 — $0.32
52-Week Range
N/A
Short Interest
N/A
Cash Runway
N/A
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 25%
LLeader vs LaggardpassRS: 14
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionpassBullish

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
HIQ -25.0%NOX +22.0%VHL +20.0%EBR +18.4%ICR +16.7%
Compare:RGT vs HIQRGT vs NOXRGT vs VHL
Share this analysis

Track RGT and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required